摘要
目的 观察康氏２号方联合甘利欣抗肝炎后肝纤维化的临床疗效。方法 ６０例 慢性乙型肝炎患者随机分为２组，对照组３０例用甘利欣注射液１５０ ｍｇ加１０％葡萄糖注射液２５０ｍｌ 静脉滴注，治疗组３０例在对照组治疗基础上加用康氏２号方，每次 １包（１０ ｇ，每ｇ含生药 ２．０９ ｇ），１ 日 ２次口服。２组均３个月为 １个疗程。２组病例均每２周查１次肝功能，每月查１次血清肝纤维 化指标。结果（１）治疗组在治疗后４项肝纤维化指标有下降，有非常显著性差异（Ｐ＜０．０１）；（２） 对照组在治疗后４项肝纤维化指标有下降，其中层粘蛋白（ＬＮ）、透明质酸（ＨＡ）有非常显著性差异 （Ｐ＜０．０１），Ⅲ型前胶原（ＰＣⅢ）Ⅳ型肝原（ＣⅣ）有显著性差异（Ｐ＜０．０５）；（３）治疗后治疗组与 对照组４项肝纤维化指标比较，ＨＡ、ＰＣⅢ，ＣⅣ有显著性差异（Ｐ＜０．０５），ＬＮ有非常显著性差异（Ｐ ＜０．０１）；（４）治疗组的肝功能复常时间比对照组早，２组有显著性差异（Ｐ＜０．０５）。结论 康氏２ 号方联合甘利欣注射液具有明显的抗肝炎后肝纤维化的作用，并在改善肝功能方面有协同作用。
Objective To observe the effect of hepatic fibrosis from chronic hepatitis treated with improvement perception of Kangshi combined with Ganlixin injection. Methods 60 cases of hepatic fibrosis from chronic hepatitis were randomly allocated to two groups. In control group ( n =30) only Ganlixin injection was used, and in treatment group ( n =30) Combination of Ganlixin injection and improvement perception of Kangshi was carried on, with a course of three months in both groups. Results 4 markers of hepatic fibrosis after treatment in treatment group was obviously lower than those in control group after treatment ( P < 0.05, or 0.01), at same time there were significant differences in 4 markers of hepatic fibrosis between before and after treatment in both groups. Recovery duration of liver function in treatment group ( 6.4286 +- 2.897 ) was shorter than that in control group (8.1667 +- 3.0598, P < 0.05). Conclusion Therapy of improvement perception of Kangshi combined with Ganlixin injection plays a role on the treatment of hepatic fibrosis from chronic hepatitis.
出处
《河北中医》
2001年第8期565-568,共4页
Hebei Journal of Traditional Chinese Medicine
